Abstract:Abstract Background Stereotactic radiosurgery (SRS) is preferred to whole brain radiotherapy (WBRT) for the treatment of patients with a limited number of brain metastases, both as primary treatment and after surgery. SRS can be delivered in a single fraction (SF) or in multiple fractions (MF) depending on tumor size and location. The aim of this single-center retrospective study was to evaluate intracranial control and overall survival (OS) in patients who received SF and MF SRS for brain metastases. Material and Methods All patients treated with primary SRS for brain metastases at Aarhus University Hospital between 2015 and 2020 were identified. Independent of undergoing surgery, SF SRS (20 Gy) was administered for targets (gross tumor volume) <2 cm in diameter and MF SRS (24-27 Gy in 3 fractions) for targets >2 cm. SRS was not combined with WBRT. Treatment response was evaluated by 3-monthly MRI-scan. To evaluate intracranial control, first events were scored as local-only failure (tumor progression at the SRS treatment site), distant failure (tumor progression not at the SRS site), and combined failure (local and distant failure). Actuarial incidence of local failure (local-only and combined) and OS were estimated using the Kaplan-Meier method. To analyze the association of SF and MF SRS with local failure and OS, multivariable Cox regression analyses were used. Results The consecutive cohort consisted of 196 patients treated for 275 brain metastases. The most frequent primary disease was non-small cell lung cancer (NSCLC n=96), followed by renal cell carcinoma (n=26) and breast cancer (n=22). SRS was delivered to 1 (n=133), 2 (n=49), 3 (n=12), and 4 (n=2) targets per patient. SF and MF SRS was used in 99 (51%) and 97 (49%) patients, respectively. In 40 patients, SRS was administered after surgery (SF n=7, MF n=33). At a median (range) follow-up of 10 (0-93) months, 111 (57%) patients had intracranial progression, and 159 (81%) patients died. Local-only/distant/combined failure rate was 23 and 42%/59 and 35%/18 and 23%, in SF and MF SRS respectively. The median time to local failure was respective 9.0 (95% CI 5.4-12.6) and 6.0 (95% CI 5.0-7.0) months in the SF and MF SRS group. SF SRS and surgery were independently associated with a longer time to local failure. Salvage WBRT, SRS, and re-operation were performed in respective 36, 13, and 26 patients. Histopathological radiation necrosis was observed in 5 patients. All patients with necrosis had a primary diagnosis of NSCLC, and 4/5 patients were treated with SF SRS. For the total group, the median OS was 10.0 (95% CI 8.0 - 12.0) months. PS<2, surgery, stable extracranial disease and SF SRS were associated with a longer survival. Conclusion MF SRS was associated with a higher rate of and shorter time to local failure, and was a poor prognostic factor for survival, which is in line with the selection of patients with more unfavorable brain metastases for this treatment.

Epid-37. Prognosis Of Brain Metastases Patients With Whole Brain Radiation Therapy (Wbrt) Vs Non-Wbrt At The National Cancer Center Of Indonesia, Dharmais Hospital

HELICAL TOMOTHERAPY FOR WHOLE-BRAIN IRRADIATION WITH INTEGRATED BOOST TO MULTIPLE BRAIN METASTASES: DOSIMETRIC ANALYSISANDCLINICAL OUTCOMES

Whole Brain Radiotherapy-Based Combined Modality Treatment of Brain Metastases from Non-Small Cell Lung Cancer: A Retrospective Analysis of Prognostic Factors

Survival Effect Difference of Whole-Brain Radiation Therapy and TKIs in Patients with Brain Metastases from Non-Small Cell Lung Cancer Stratified by EGFR Mutation Status

Whole-Brain Radiation Therapy With Simultaneous Integrated Boost Versus Whole-Brain Radiation Therapy Plus Stereotactic Radiosurgery for the Treatment of Brain Metastasis From Lung Cancer

Outcome of Brain Metastases from HER 2–positive Breast Cancer: Difference in Survival Benefit from Anti-HER 2 Treatment after WBRT with Regard to Prior Targeted Therapy

Prognostic Factors and Impact of Therapeutic Intervention in Patients With Brain Metastases at the Initial Presentation

Profile of Primary Brain Tumor Patients Who Received Radiotherapy at Hasan Sadikin General Hospital Bandung in 2020-2021

Real-world outcomes of breast cancer patients with brain metastases treated with radiotherapy in Ontario: A population-based study.

Relationship Between WBRT Total Dose, Intracranial Tumor Control, and Overall Survival in NSCLC Patients with Brain Metastases - a Single-Center Retrospective Analysis

Analysis of prognostic factors and index model in patients with brain metastases after whole-brain radiotherapy

Whole Brain Radiotherapy (WBRT) for Brain Metastases

Analysis of prognostic factors and prognostic indices in breast cancer patients with brain metastases after whole-brain radiotherapy

The Analysis of Effect about Different Therapies on Brain Metastases from Non-Small Cell Lung Cancer

P11.11.B Stereotactic radiosurgery for brain metastases;outcome and prognostic factors in patients treated with single-fraction and multiple-fractions

Survival Impact of Postoperative Whole-brain Radiotherapy and Systemic Chemotherapy After Surgical Resection of Brain Metastases

A Dutch phase III randomized multicenter trial: whole brain radiotherapy versus stereotactic radiotherapy for 4-10 brain metastases

The Current Situation and Advances in the Whole Brain Radiation Therapy for Newly-diagnosed Brain Metastases

Reirradiation of Whole Brain for Recurrent Brain Metastases: A Case Report of Lung Cancer With 12-Year Survival

The indication of palliative whole-brain radiotherapy for patients with brain metastases: a simple prognostic scoring system in the era of stereotactic radiosurgery

Epid-14. Patterns Of Care And Prognostic Factors For Patients With Brain Metastases From Colon Cancer: A Real-World Study